Titan Spine received approval for the Endoskeleton interbody fusion device in New Zealand and Australia.
The Asia Pacific spinal implant and bone growth substitute market, which includes Australia, is expected to grow to $7 billion by 2022.
The Endoskeleton device features Titan Spine's proprietary implant surface technology with a unique combination of roughened topographies at the macro, micro and cellular levels. The surface level combination is designed to create an enhanced environment for bone growth at the cellular level. This encourages natural bone morphogenic protein production.
The device has also entered the United States and European Union markets. "Entry into our two most recent markets underscores the increasing global adoption of our titanium implants that feature a unique surface technology designed to participate in the fusion process by upregulating the body's own bone growth factors," said Titan Spine President Kevin Gemas.
John Sutcliffe, MD, London Spine Clinic founder, is the first in the United Kingdom to use Titan Spine's interbody fusion technology. "I am pleased to initiate use of Titan Spine's Endoskeleton TAS interbody device and its specialized surface treatment," said Dr. Sutcliffe in a news release. "It is my belief that surface technology is the next significant innovation for spinal fusions due to the ability to affect cellular response that promotes a more favorable osteogenic environment as compared to PEEK polymer implants."
In January, Titan Spine received five new patents from the U.S. Patent and Trademark Office related to Endoskeleton interbody devices. The company now has 40 patents awarded and under review.
More Articles on Spine Devices:
The Volatile Spine Device Market: Mergers, IPOs & International Growth
NuVasive's Growth: 5 Key Qualities of the Newly-Released Monitoring Platform
Integra LifeScience Turns 25: 5 Things to Know